EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study

Akihiko Sugino iD, Yoshiyuki Miyazawa iD, Shun Nakazawa, Yusuke Tsuji, Yuji Fujizuka, Seiji Arai iD, Yoshitaka Sekine iD, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki iD

International Journal of Urology · 2026

DOI: 10.1111/iju.70433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Akihiko Sugino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gunma University Graduate School of Medicine & Gunma University Hospital, Department of Urology, Maebashi, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Active surveillance (AS) offers a strategy to limit unnecessary treatment of prostate cancer while maintaining oncologic safety, yet its adoption in Japan remains limited. To provide Japan‐specific evidence, we evaluated the clinical outcomes of patients undergoing AS at our institution.

Methods

We retrospectively reviewed 86 patients who selected AS between 2012 and 2024. Eligibility criteria included ≤ cT2a disease, prostate‐specific antigen (PSA) level of ≤ 10 ng/mL, Gleason score (GS) of 3 + 3, and 2 or fewer positive cores, with selected inclusion of GS 3 + 4 or 4 + 3 based on patient preference. AS discontinuation was based on clinical or pathological progression or patient preference. This study was approved by the institutional review board of Gunma University (approval no. IRB2025‐033, 2310).

Results

The mean observation period was 48 months. No prostate cancer–specific deaths occurred. AS persistence rates were 89% at 1 year, 55% at 5 years, and 27% at 10 years. Older age (≥ 75 years) was associated with longer AS persistence ( p = 0.021). Overall, 69% of patients underwent repeat biopsy, most commonly at 1 year. Pathological upgrading occurred in 35% at the first and second repeat biopsies and in 20% at the third. Acceptance of the 1‐year repeat biopsy increased from 46% in the early period (2012–2016) to 64% in the later period (2017–2024).

Conclusions

AS demonstrated favorable long‐term safety and durability. Improving adherence to repeat biopsy protocols may further enhance AS management in Japan. Registry and Registration No. of the Study/Trial N/A

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWatchful WaitingHumansMaleRetrospective StudiesAgedNeoplasm GradingJapanProstate-Specific AntigenMiddle AgedDisease ProgressionProstateAged, 80 and overBiopsyBiopsy, Large-Core NeedleAge Factors

Stichwörter der Autor:innen

active surveillancelocalizedprostate cancer

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Gunma University Graduate School of Medicine & Gunma University Hospital, Department of Urology, Maebashi, Japan.

ORCID-Profile: Akihiko Sugino, Yoshiyuki Miyazawa, Seiji Arai, Yoshitaka Sekine, Kazuhiro Suzuki

Zitieren

APA

Sugino, A., Miyazawa, Y., Nakazawa, S., Tsuji, Y., Fujizuka, Y., Arai, S., Sekine, Y., Nomura, M., Koike, H., Matsui, H., & Suzuki, K. (2026). Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study. International Journal of Urology. https://doi.org/10.1111/iju.70433

Vancouver

Sugino A, Miyazawa Y, Nakazawa S, Tsuji Y, Fujizuka Y, Arai S, et al. Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study. International Journal of Urology. 2026. doi:10.1111/iju.70433

BibTeX
@article{Sugino2026,
  author = {Sugino, Akihiko and Miyazawa, Yoshiyuki and Nakazawa, Shun and Tsuji, Yusuke and Fujizuka, Yuji and Arai, Seiji and Sekine, Yoshitaka and Nomura, Masashi and Koike, Hidekazu and Matsui, Hiroshi and Suzuki, Kazuhiro},
  title = {Active Surveillance for Localized Prostate Cancer: A Retrospective Single‐Center Study},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70433}
}
Kostenlos starten →